Skip to Content

InnoCare Pharma Ltd 09969

Morningstar Rating
HK$4.89 0.00 (0.00%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

09969 is trading at a 73% premium.
Price
HK$4.89
Fair Value
HK$1.77
Uncertainty
Very High
1-Star Price
HK$22.58
5-Star Price
HK$3.65
Economic Moat
Jzt
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if 09969 is a good fit for your portfolio.

News

Trading Information

Previous Close Price
HK$4.89
Day Range
HK$4.834.97
52-Week Range
HK$4.038.38
Bid/Ask
HK$4.89 / HK$4.90
Market Cap
HK$8.62 Bil
Volume/Avg
1.6 Mil / 3.4 Mil

Key Statistics

Price/Earnings (Normalized)
Price/Sales
11.39
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield
0.07%

Company Profile

InnoCare Pharma Ltd is a commercial-stage biopharmaceutical company. It discovers, develops, and commercializes drugs for the treatment of cancer and autoimmune diseases. The company's main product pipeline includes orelabrutinib, ibrutinib, zanubrutinib, tafasitamab, ICP-490, ICP-B02, ICP-248, ICP-192, ICP-723, and ICP-189, among others. Its products are mainly used to treat hematological tumors, solid tumors, and autoimmune diseases. The company is also developing products for the treatment of autoimmune diseases caused by abnormal B-cell or T-cell function.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Mid Growth
Total Number of Employees
1,089

Comparables

Valuation

Metric
09969
06628
01244
Price/Earnings (Normalized)
Price/Book Value
1.120.631.09
Price/Sales
11.399.841.42
Price/Cash Flow
Price/Earnings
09969
06628
01244

Financial Strength

Metric
09969
06628
01244
Quick Ratio
4.101.092.16
Current Ratio
4.191.232.19
Interest Coverage
−31.46−28.87−72.21
Quick Ratio
09969
06628
01244

Profitability

Metric
09969
06628
01244
Return on Assets (Normalized)
−7.58%−22.79%−19.25%
Return on Equity (Normalized)
−10.64%−38.31%−28.69%
Return on Invested Capital (Normalized)
−11.54%−26.22%−23.70%
Return on Assets
09969
06628
01244
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Novo Nordisk A/S ADR
NVO
LgwthcjkNghbf$632.3 Bil
Vertex Pharmaceuticals Inc
VRTX
HqvtlrqrwYbjzfvs$126.7 Bil
Regeneron Pharmaceuticals Inc
REGN
YlmvfdpyhKsdhvf$119.2 Bil
Moderna Inc
MRNA
LpyjklngJhz$46.6 Bil
Alnylam Pharmaceuticals Inc
ALNY
RxybbsjhwSgbrnn$32.4 Bil
argenx SE ADR
ARGX
PqtftnplCqj$27.6 Bil
BioNTech SE ADR
BNTX
JvtrkzpvxYmj$20.3 Bil
Biomarin Pharmaceutical Inc
BMRN
YglfmghZdltmgt$16.1 Bil
United Therapeutics Corp
UTHR
HvvxdvtvrPnbyt$14.5 Bil
Incyte Corp
INCY
FqvmxnxQgxldlz$12.7 Bil

Sponsor Center